Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Pilot Study to Examine the Effect of Egb761 on Plasma Biomarker Levels and on Cognitive Function in Patients With MCI
Sponsor: Hadassah Medical Organization
Summary
The goal of this clinical trial is to learn if the drug Egb761, produced from Ginkgo Biloba extract, works to improve the blood level of a biomarker of Alzheimer's disease, called phosphorylated-tau217 (p-tau217), which serves as a biomarker for disease activity in the brain. The main questions it aims to answer are: Does drug Egb761 lower the plasma level of p-tau217 in patients with mild cognitive impairment? Does drug Egb761 improve cognitive and behavioral functions in these patients? Does Egb761 affect the blood levels of neurofilament-light (Nfl) and glial-fibrillary-acidic-protein (GFAP), which serve as additional biomarkers for brain disease activity? Participants will: Take Egb761 twice daily for 6 months Visit the clinic once every 3 months for checkups and tests Keep a diary of their symptoms
Official title: Is Cerebonin (Egb761) a Disease-modifying Therapy in Mild Cognitive Impairment
Key Details
Gender
All
Age Range
65 Years - Any
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2024-08-20
Completion Date
2026-12
Last Updated
2025-12-17
Healthy Volunteers
No
Interventions
Ginkgo Biloba Extract 761
Each participant will receive two 120mg Egb761 pills per day along the 6 month trial
Locations (1)
Hadassah medical Center
Jerusalem, Israel